Our mission is to address critical unmet medical needs through the development of targeted therapies that go beyond symptom relief to directly target the root causes of diseases
Myosin Therapeutics was founded in 2020 by Dr. Courtney Miller, Dr. Pat Griffin, and Dr. Ted Kamenecka stemming from their association with Scripps Research. Dr. Miller’s research group made a groundbreaking discovery, identifying nonmuscle myosin II as a promising therapeutic target for preventing relapse in individuals with methamphetamine use disorder. The innovative approach led to the team receiving a grant for medications development from the NIH’s Blueprint Neurotherapeutics Network.
With this support from the NIH, the team spend the next five years developing MT-110, a pioneering drug that targets the nonmuscle myosin II receptor for the treatment in methamphetamine use disorder.
In 2021, the company in collaboration with the Mayo Clinic, identified that nonmuscle myosin II (NMII) A and B was a novel molecular target for the treatment of cancer. Following an extensive medical chemistry campaign, the company introduced MT-125 as its lead drug candidate for addressing Glioblastoma.
The company secured an exclusive license agreement for the intellectual property related to MT-110, MT-125, and associated compounds from Scripps Research (University of Florida).
In early 2023, the company received funding from the National Cancer Institute (NCI) to further advance MT-125 through IND-enabling activities. Additionally, the company successfully raised private capital to further expand its pipeline of drug candidates for different cancer indications, and accelerating the development timelines for MT-125, with the goal of entering clinical trials by the end of 2024.